RYONCIL turns Mesoblast into a real business

A real launch, not a promise

Mesoblast has crossed the line from research story to commercial biotech. RYONCIL, its first approved product, produced $49M of net sales in the first half of FY26. Gross margin was 93%, which means the direct cost to make and supply the drug was low compared with sales.

The bull case is simple. A small launch team is reaching the transplant centers that matter, with 49 centers onboarded and 30 listing RYONCIL on formulary. Formulary means the hospital has approved the drug for use. Management guides to $110M to $120M of FY26 RYONCIL net revenue, and payers have so far covered the drug without step-therapy rules that force patients to try another drug first.

The bear case is price and proof. RYONCIL is priced at $194,000 per infusion, and the internal thesis frames a full treatment course at about $1.5M. That price must hold as more hospitals use it and more insurers see claims. Mesoblast also still has costly trials to run.

The next swing factors are pipeline events. The company plans a full BLA filing for REVASCOR in LVAD patients next quarter, rather than the earlier accelerated path. It also needs to start the adult GVHD pivotal trial with Jakafi and finish enrollment in the chronic low back pain Phase 3 study.

Tiny market first, partners later

Mesoblast sells allogeneic cell therapy. Allogeneic means the cells come from donors, not from each patient. That matters because donor-derived cells can be made in batches and shipped to hospitals, more like a drug than a custom procedure.

For pediatric GVHD, the company uses a narrow sales model. It started with 9 key account managers focused on 45 major U.S. transplant centers that represent 80% of the potential patient volume. This fits an orphan disease, where a small number of expert hospitals treat most patients.

For larger markets, Mesoblast is not trying to build a huge salesforce everywhere. In areas like chronic low back pain and adult heart failure, it expects to use regional partners, including its existing EU partnership with Grunenthal, so outside companies can help with distribution.

The moat is intellectual property and manufacturing know-how. Mesoblast says it has more than 1,000 patents granted or filed, with key protection lasting into 2037 to 2043. The weak point is that patents do not remove clinical, regulatory, or payer risk.

One approved drug, several shots

FY25 revenue mix is already outdated

The mix below uses FY2025 Form 20-F revenue categories: $11.263M of net product sales and $5.935M of royalty revenue. Because RYONCIL produced $49M in 1H FY26 after launch, the current business is likely more product-heavy than the FY25 mix shows.

What could still break

In one breath